{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:40:22Z","timestamp":1790624422336,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.03.024","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:43Z","timestamp":1782992203000},"page":"770-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating systemic therapy in the earlier stages of liver cancer"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-9534","authenticated-orcid":false,"given":"Maria","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Vilgrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.03.024_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.024_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2026.03.024_bib3","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib9","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"0","author":"Do-Youn","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2026.03.024_bib10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2025.03.019","article-title":"Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study","volume":"83","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2 -Rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib15","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib17","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in Human Epidermal Growth factor Receptor 2\u2013Expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.jhep.2026.03.024_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid Tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.jhep.2026.03.024_bib19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib21","doi-asserted-by":"crossref","unstructured":"Ascierto Paolo A., Del Vecchio Michele, Merelli Barbara, et al. Nivolumab for Resected Stage III or IV Melanoma at 9 Years. New Engl J Med n.d.;0. https:\/\/doi.org\/10.1056\/NEJMoa2504966.","DOI":"10.1056\/NEJMoa2504966"},{"key":"10.1016\/j.jhep.2026.03.024_bib22","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after Nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib24","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after Chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"New Engl J Med"},{"issue":"18","key":"10.1016\/j.jhep.2026.03.024_bib27","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant Dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib28","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib30","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and Exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib31","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1200\/JCO.22.01283","article-title":"Reply to J. Edeline et al.","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","article-title":"Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival","volume":"70","author":"Llovet","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib34","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/hep.27881","article-title":"Pattern of tumor progression in liver cancer: the missing partner in trial design","volume":"62","author":"Reig","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.024_bib35","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update","author":"Reig","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2026.03.024_bib38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1872-034X.2010.00674.x","article-title":"Response evaluation criteria in cancer of the liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version)","volume":"40","author":"Kudo","year":"2010","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2026.03.024_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib42","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.024_bib43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib44","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer","volume":"70","author":"Greten","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e16279","article-title":"Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: a randomized, open-label multicenter trial","volume":"43","author":"Xia","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib49","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib50","doi-asserted-by":"crossref","unstructured":"Galle P. IKF-035\/ABC-HCC: a phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. ESMO Meet 2025:LBA51.","DOI":"10.1016\/j.annonc.2025.09.063"},{"key":"10.1016\/j.jhep.2026.03.024_bib51","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.024_bib52","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.024_bib53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.123.266211","article-title":"Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial","volume":"65","author":"Garin","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90 Y radioembolization versus drug-eluting Bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2026.03.024_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","volume":"10","author":"de la Torre-Al\u00e1ez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib56","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib57","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2279","article-title":"LBA39 Updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)","volume":"35","author":"Yopp","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.024_bib59","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2025.08.042","article-title":"Strategies to address non-proportional hazards between survival curves-Lessons from phase III trials in hepatocellular carcinoma","volume":"84","author":"Mauro","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.477","article-title":"Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: the phase 3 keynote-937 study","volume":"44","author":"Chan","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib61","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib62","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib63","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib64","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib65","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib66","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib67","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.024_bib68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib70","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12885-021-08033-x","article-title":"PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma","volume":"21","author":"Pinato","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.024_bib73","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.024_bib74","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D\u2019Alessio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","author":"Wang","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.03.024_bib76","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-17-2899","article-title":"Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2026.03.024_bib77","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2026.03.024_bib79","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.01.009","article-title":"Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies","volume":"164","author":"Edeline","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib80","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.024_bib81","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2026.03.024_bib82","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib83","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4008","article-title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: final results from the phase III AIO\/CALGP\/ACO-GAIN-Trial","volume":"43","author":"Goetze","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.jhep.2026.03.024_bib84","article-title":"Neoadjuvant toripalimab plus lenvatinib and GEMOX in resectable, high-risk intrahepatic cholangiocarcinoma: a randomized, multicenter, open-label phase II-III clinical trial","author":"Shi","year":"2025","journal-title":"ESMO Meet"},{"key":"10.1016\/j.jhep.2026.03.024_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1390","article-title":"97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): results of a randomized, multicenter, open-label, phase II trial (DEBATE)","volume":"34","author":"Yoo","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.03.024_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.10.105","article-title":"278P Randomized phase II trial of neoadjuvant gemcitabine-cisplatin (GemCis) with or without durvalumab (D) for localized biliary tract cancers (BTC): final clinical and biomarker analysis of the DEBATE study","volume":"36","author":"Yoo","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:53:14Z","timestamp":1789491194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826001509"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating systemic therapy in the earlier stages of liver cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}